COMP <GO>
AXSM vs MRK // DIVIDEND YIELD & FCF PAYOUT SAFETY
Axsome Therapeutics Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: AXSM 3
— MRK 11
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: MRK
LAST: $144.43 (+0.68%) • MKT CAP: $7.51B
dividend-safety
0.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
dividend-safety
2.26%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AXSM VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AXSM | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.90% | 20.70% | -42.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.25% | 3.42% | -4.67 | MRK | /fcf-yield <GO> |
| Operating Margin | -26.10% | 34.30% | -60.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | -28.70% | 28.10% | -56.80 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 65.50% | 1.30% | +64.20 | AXSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.34 | 5.19 | +0.15 | AXSM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.60% | +0.80 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 24.3 | 56.9 | -32.54 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.92 | +0.23 | AXSM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.0x | 18.4x | +16.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.51B | $361.02B | -$353.51B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AXSM REV | MRK REV | AXSM GROSS % | MRK GROSS % | AXSM FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $638.5M | $65.01B | 44.0% | 74.8% | -$93.9M | $12.36B |
| FY 2024 | $385.7M | $64.17B | 44.0% | 76.3% | -$128.7M | $18.10B |
| FY 2023 | $270.6M | $60.12B | 44.0% | 44.0% | -$157.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AXSM // BETA 1.15
MRK // BETA 0.92